Who is Algernon Pharmaceuticals Inc (agw0 F)?

AGN Neuro is the world’s first company to investigate DMT for the tre Find the latest Algernon Pharmaceuticals Inc. (AGW0.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

How many stock options did Algernon pharmaceuticals issue?

VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company reports that the Company has granted 96,000 stock options exercisable at $4.

Who is Algernon's CEO?

Algernon Pharmaceuticals CEO Christopher Moreau said the company has announced that its subsidiary Algernon NeuroScience has dosed the first subject in the Phase 1 DMT clinical stroke study. Moreau told Proactive this dosing was in the Netherlands where the study is being conducted at the Centre for Human Drug Research in Leiden.

What does Algernon do?

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.